Friday, February 4, 2022

10:00 Welcome & Introductions
Dr. Grace Lee (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

10:15 Coronavirus Disease 2019 (COVID-19) Vaccines
Dr. Matthew Daley (ACIP, WG Chair)
Dr. Rituparna Das (Moderna)

mRNA 1273 COVID-19 vaccine BLA safety and efficacy data

11:00 Break

11:10 Public Comment

11:45 Updates on myocarditis and pericarditis following Moderna COVID-19 vaccination
Dr. Tom Shimabukuro (CDC/NCEZID)
Dr. Ian Kracalic (CDC/NCEZID)
Dr. Keipp Talbot (ACIP, VaST Chair)

Update on myocarditis outcomes: MOVING

VaST assessment

12:30 Break

1:00 GRADE: Moderna COVID-19 vaccine
Dr. Megan Wallace (CDC/NCIRD)
Dr. Sara Oliver (CDC/NCIRD)

EtR Framework: Moderna COVID-19 vaccine primary series in adults ≥18 years of age
Discussion

VOTE

Moderna COVID-19 vaccine for individuals ≥18 years of age
Dr. Sara Oliver (CDC/NCIRD)

2:30 Break

Updates to Clinical Considerations
Dr. Elisha Hall (CDC/NCIRD)

Canadian experience and evidence with COVID-19 vaccine primary series extended intervals
Dr. Matthew Tunis (Public Health Agency of Canada), Dr. Bryna Warshawsky (Public Health Agency of Canada), Ms. Susanna Ogunnaike-Cooke (Public Health Agency of Canada)

VSD: Myocarditis after Moderna and Pfizer/BioNTech COVID-19 vaccine
Dr. Nicky Klein (KPNC)

Myocarditis and COVID-19 vaccine intervals: International data and policies
Ms. Danielle Mouia (CDC/NCIRD)

Summary and Work Group Interpretation: Extended intervals for mRNA COVID-19 vaccines
Dr. Sara Oliver (CDC/NCIRD)

Discussion

5:00 Adjourn